Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Jun
16
Today In Oncology
Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings
Frailty Following Chemotherapy May Be Linked to Poorer Survival in Older Women With Breast Cancer
Poor Agreement Reported Among Diagnostic Tests for Breast Cancer Related Lymphedema
Metabolic Syndrome May Increase Risk of Cancer Recurrence Subsequent Mortality Among Breast Cancer Survivors
CAP Issues New and Updated Cancer Protocols
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo